The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp464
DIET AND MICROBIOME-BASED THERAPIES FOR IBD - WHAT ARE THE DATA?
Date
May 7, 2023
Explore related products in the following collection:
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
BACKGROUND The gut microbiome is central to Crohn’s disease (CD) pathogenesis but the relative contribution of different environmental factors to disease compositional variation is unknown…
BACKGROUND The gut microbiome is central to Crohn’s disease (CD) pathogenesis but the relative contribution of different environmental factors to disease compositional variation is unknown…